Bicara Therapeutics (BCAX) Net Cash Flow (2023 - 2026)
Bicara Therapeutics (BCAX) posted quarterly Net Cash Flow of $226.8 million for Q1 2026, up 920.29% year-over-year from $22.2 million in Q1 2025, and up 402.42% quarter-over-quarter from -$75.0 million in Q4 2025.
Bicara Therapeutics (BCAX) Net Cash Flow (2023 - 2026) Analysis & Trends
Bicara Therapeutics' Net Cash Flow history runs 4 years deep, the most recent figure standing at $226.8 million for Q1 2026.
- In Q1 2026, Net Cash Flow rose 920.29% year-over-year to $226.8 million; the TTM figure through Mar 2026 stood at -$138.6 million (down 156.34% YoY), while the FY2025 annual figure was -$393.0 million, down 251.59% from the prior year.
- Net Cash Flow for Q1 2026 stood at $226.8 million, up from -$75.0 million in the prior quarter.
- The five-year high for Net Cash Flow was $316.9 million in Q3 2024, with the low at -$264.9 million in Q3 2025.
- The 4-year median for Net Cash Flow is -$19.9 million (2024), against an average of $27.9 million.
- The sharpest annual moves came in 2025 and 2026: Net Cash Flow sank 183.6% in 2025, then soared 920.29% in 2026.
- Bicara Therapeutics' Net Cash Flow stood at $186.2 million in 2023, then sank by 116.67% to -$31.0 million in 2024, then sank by 141.53% to -$75.0 million in 2025, then surged by 402.42% to $226.8 million in 2026.
- Business Quant data shows BCAX's Net Cash Flow at $226.8 million in Q1 2026, -$75.0 million in Q4 2025, and -$264.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 407.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 17.81 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -496,000.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.14 Mn |
| 10 | Bicara Therapeutics | 1.60 Bn | 1.60 Bn | - | -226.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -226.86 Mn |
| Jun 30, 2026 | -226.86 Mn |
| Mar 31, 2026 | 226.78 Mn |
| Mar 31, 2026 | 226.78 Mn |
| Dec 31, 2025 | -74.99 Mn |
| Dec 31, 2025 | -74.99 Mn |
| Sep 30, 2025 | -264.93 Mn |
| Sep 30, 2025 | -264.93 Mn |
| Jun 30, 2025 | -25.46 Mn |
| Jun 30, 2025 | -25.46 Mn |
| Mar 31, 2025 | -27.65 Mn |
| Mar 31, 2025 | -27.65 Mn |
| Dec 31, 2024 | -31.05 Mn |
| Dec 31, 2024 | -31.05 Mn |
| Sep 30, 2024 | 316.90 Mn |
| Sep 30, 2024 | 316.90 Mn |
| Jun 30, 2024 | -12.19 Mn |
| Jun 30, 2024 | -12.19 Mn |
| Mar 31, 2024 | -14.39 Mn |
| Mar 31, 2024 | -14.39 Mn |